Keywords: Lexicon Pharma, R&D pipeline, LX42ii, Telotristat etiprate, LX1033
Lexicon Pharma updates on clinical pipeline
Article | 21 February 2013
US drug developer Lexicon Pharmaceutical (Nasdaq: LXRX) yesterday updated its drug development pipeline, highlighting progress with its LX4211, telotristat etiprate ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
